The BILCAP study results …

With the kind permission of Professor John Primrose, AMMF is now able to share the BILCAP presentation slides from the ASCO 2017 meeting.

These slides show details of the BILCAP study and its outcome.  The study looked at whether or not giving cholangiocarcinoma patients Capecitabine chemotherapy following resection would be beneficial.

The outcome is positive – Capecitabine will now be recommended to be given following resection for cholangiocarcinoma.








For more information on the results of the BILCAP study, see:


In this video Dr John Marshall of Georgetown University, and Professor John Primrose of the University of Southampton, discuss the practice-changing findings of the BILCAP study which investigated adjuvant capecitabine for biliary tract cancer (cholangiocarcinoma).  The pan-European study that Professor Primrose refers to (6:09 into the interview) is the ACTICCA-1 trial.

June 2017